By the time the FDA hands down its decision on valrox, BioMarin will be a different company — literally.
The biotech is laying off about 120 employees — 4% of its global workforce — in a slim down that will save about $50 million annually. A “significant portion” of the savings, it adds, will go toward its clinical development portfolio, early-stage pipeline, as well as the commercial launches and valrox, the hemophilia A gene therapy that already has the brand name Roctavian.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,600+ biopharma pros reading Endpoints daily — and it’s free.
SIGN UP
LOG IN
